Alzheimer disease was defined either by neuropathologic examination or, in living persons, by positron emission tomography (PET) or biofluid biomarkers of the 2 hallmark diagnostic proteinopathies, namely, β-amyloid plaques and tau neurofibrillary tangles. This evidence concerns the gene MAPT and Alzheimer disease.